What is the biological function of RPL17 protein?

RPL17 (Ribosomal Protein L17) functions as a component of the large ribosomal subunit. The ribosome is a large ribonucleoprotein complex responsible for protein synthesis in cells. Specifically, RPL17 is part of the 60S ribosomal subunit, where it plays a crucial role in the structural integrity and function of the ribosome during translation. RPL17 is also known as 60S ribosomal protein L17, 60S ribosomal protein L23, and large ribosomal subunit protein uL22 in different naming conventions . Understanding the fundamental role of RPL17 in translation machinery is essential for researchers investigating ribosome assembly, protein synthesis disorders, and related cellular processes.

What types of RPL17 antibodies are available for research?

Multiple formats of RPL17 antibodies are available for research applications:

• Host species: Primarily rabbit polyclonal antibodies, with some mouse monoclonal options (such as clone 3G11)

• Reactivity: Most commonly reactive with human samples, with many cross-reactive to mouse and rat RPL17

• Conjugation types:

  • Unconjugated primary antibodies

  • Conjugated versions including HRP-conjugated, biotin-conjugated, and FITC-conjugated antibodies

• Target regions: Antibodies targeting different epitopes of RPL17, including:

  • Full-length protein (AA 1-184)

  • N-terminal region

  • C-terminal region (AA 156-184)

  • Internal regions

The diversity of available antibodies allows researchers to select the most appropriate tool based on their specific experimental needs and target species.

What applications are RPL17 antibodies validated for?

RPL17 antibodies have been validated for multiple experimental applications with specific recommended dilutions:

Researchers should note that optimal dilutions may vary depending on sample type and experimental conditions. Validation data from vendors often includes Western blot images showing expected band sizes and immunostaining patterns .

What are the optimal conditions for Western blot detection of RPL17?

For optimal Western blot detection of RPL17, consider the following protocol details based on validated methods:

• Sample preparation: Total cell lysates from HeLa or HepG2 cells show strong RPL17 expression. Tissue samples from pancreas (human, mouse, rat) also provide good signal .

• Gel conditions: Use 12% SDS-PAGE gels for optimal separation around the 21.4 kDa size range of RPL17 .

• Antibody dilution: Primary antibody dilutions between 1:1000-1:10000 are typically effective, with 1:1000 being a good starting point for most RPL17 antibodies .

• Expected results: A clear band at approximately 21 kDa should be visible. Some antibodies may detect secondary bands representing isoforms or post-translational modifications .

• Controls: Consider using pancreatic tissue lysates as positive controls, as they consistently show strong RPL17 expression .

When troubleshooting weak or absent signals, consider adjusting protein loading (30 μg of total protein is often used in published protocols), optimizing transfer conditions, or trying antibodies targeting different epitopes of the protein .

How should RPL17 antibodies be handled and stored for maximum stability?

To maintain antibody performance and extend shelf life, follow these evidence-based storage and handling recommendations:

• Storage temperature: Store RPL17 antibodies at -20°C for long-term preservation .

• Aliquoting: Upon receipt, create small working aliquots to avoid repeated freeze-thaw cycles, which can degrade antibody quality .

• Buffer conditions: Most RPL17 antibodies are supplied in PBS with 0.09% sodium azide as a preservative . This buffer maintains antibody stability during storage.

• Concentration: Commercial antibodies are typically provided at concentrations around 1 mg/mL . Consider dilution factors when planning experiments.

• Thawing procedure: Thaw antibodies gradually on ice rather than at room temperature to preserve binding activity.

• Contamination prevention: Use sterile techniques when handling antibodies to prevent microbial contamination.

Following these guidelines will help maintain antibody performance across multiple experiments and maximize the value of research reagents.

What immunohistochemistry (IHC) protocols are recommended for RPL17 detection in tissue sections?

For successful immunohistochemical detection of RPL17 in tissue sections, follow these validated protocol recommendations:

• Fixation and embedding: Paraformaldehyde fixation and paraffin embedding have been validated for RPL17 antibodies .

• Antigen retrieval:

  • Primary recommendation: TE buffer (pH 9.0) for heat-induced epitope retrieval

  • Alternative option: Citrate buffer (pH 6.0)

• Blocking: Standard blocking with serum matching the species of the secondary antibody helps reduce background.

• Primary antibody dilution: Start with 1:50-1:100 dilution for IHC-P applications .

• Incubation conditions: Typically overnight at 4°C or 1-2 hours at room temperature.

• Detection systems: Both chromogenic (DAB) and fluorescent detection systems have been validated.

• Positive control tissues: Human pancreatic tissue (normal or cancerous) has been validated as a positive control for RPL17 expression .

Researchers should optimize these conditions based on their specific tissue type and fixation methods. When working with frozen sections (IHC-F), additional optimization may be required as most antibodies are primarily validated for paraffin sections .

How can I determine if my RPL17 antibody is detecting the correct protein?

Validating the specificity of your RPL17 antibody is crucial for research integrity. Consider implementing these verification strategies:

• Molecular weight confirmation: RPL17 should appear at approximately 21.4 kDa on Western blots. Verify your observed band matches this expected size .

• Positive control samples: Run known RPL17-expressing samples such as HeLa cells, HepG2 cells, or pancreatic tissue alongside your experimental samples .

• Knockout/knockdown controls: If available, use RPL17 knockout or knockdown samples as negative controls.

• Multiple antibodies approach: Test antibodies targeting different epitopes of RPL17 (N-terminal vs. C-terminal) and compare their detection patterns .

• Immunoprecipitation validation: For more rigorous validation, perform immunoprecipitation followed by mass spectrometry to confirm the identity of the pulled-down protein .

• Cross-reactivity assessment: If working with non-human samples, verify cross-reactivity claims. Some RPL17 antibodies are predicted to react with rat and cow RPL17 based on sequence homology but may require validation .

These steps help ensure experimental observations truly reflect RPL17 biology rather than non-specific binding or artifacts.

What alternative methods exist for studying RPL17 beyond antibody-based techniques?

While antibodies are valuable tools, researchers can employ complementary approaches to study RPL17:

• mRNA expression analysis:

  • RT-qPCR for quantitative measurement of RPL17 transcript levels

  • RNA-seq for genome-wide expression profiling including RPL17

  • In situ hybridization to visualize RPL17 mRNA localization in tissues

• Protein tagging strategies:

  • CRISP/Cas9-mediated endogenous tagging of RPL17 with fluorescent proteins or epitope tags

  • Expression of tagged RPL17 constructs for real-time imaging or affinity purification

• Mass spectrometry approaches:

  • Ribosome profiling to study RPL17's role in translation

  • Proximity labeling (BioID, APEX) to identify RPL17 interaction partners

• Functional assays:

  • Ribosome assembly assays to assess the impact of RPL17 depletion

  • Translation efficiency measurements using reporter constructs

  • Polysome profiling to analyze ribosome biogenesis

These alternative approaches can provide mechanistic insights into RPL17 function that complement antibody-based detection methods and help overcome potential limitations of immunological detection.

What are the challenges in detecting RPL17 in specific subcellular compartments?

Detecting RPL17 in distinct subcellular locations presents several technical challenges that researchers should consider:

• Predominant nucleolar/cytoplasmic localization: As a ribosomal protein, RPL17 is primarily found in nucleoli (site of ribosome biogenesis) and cytoplasm (site of mature ribosome function). Distinguishing between these pools requires high-resolution imaging techniques .

• Fixation considerations: Different fixation methods can affect epitope accessibility and apparent localization:

  • Paraformaldehyde fixation (commonly used with RPL17 antibodies) preserves cellular architecture but may reduce accessibility of some epitopes

  • Methanol fixation might better preserve certain epitopes but can disrupt membrane structures

• Background reduction strategies:

  • Use specific blocking reagents to reduce non-specific binding

  • Optimize antibody dilutions (1:200 dilution has been validated for IF with RPL17 antibodies)

  • Consider signal amplification systems for detecting low-abundance pools

• Co-localization studies: For definitive subcellular localization, co-stain with established markers:

  • Nucleolar markers (fibrillarin, nucleolin) for ribosome biogenesis sites

  • Endoplasmic reticulum markers to track sites of active translation

  • Nuclear envelope markers to distinguish nucleoplasmic from cytoplasmic ribosomes

• Super-resolution techniques: Consider STED, STORM, or PALM microscopy for detailed localization studies beyond the diffraction limit of conventional microscopy.

Immunofluorescence analysis has been successfully performed on paraformaldehyde-fixed HeLa cells using RPL17 antibodies at 1:200 dilution, with nuclear counterstaining using Hoechst 33342 .

How does RPL17 expression vary across different cell lines and tissues?

RPL17 expression patterns show tissue-specific and cell-type variation that researchers should consider when designing experiments:

• Validated expression in cell lines:

  • Strong expression confirmed in HeLa cells (cervical cancer)

  • High expression in HepG2 cells (liver hepatocellular carcinoma)

  • Detectable in various other transformed cell lines

• Tissue-specific expression patterns:

  • Particularly high expression in pancreatic tissue across species (human, mouse, rat)

  • Detectable in most tissues due to the fundamental role of ribosomes in protein synthesis

  • May show variable levels based on protein synthesis demands of specific tissues

• Expression in pathological conditions:

  • Detected in human pancreatic cancer tissue samples

  • May show altered expression in conditions with dysregulated protein synthesis

• Considerations for experimental design:

  • Use appropriate positive controls (HeLa, HepG2, or pancreatic tissue) when establishing new detection protocols

  • Consider tissue-specific expression levels when optimizing antibody dilutions

  • For quantitative studies, account for baseline expression differences between tissues or cell types

Understanding the natural variation in RPL17 expression helps establish appropriate experimental controls and interpret results in different biological contexts.

What is known about RPL17's involvement in disease processes?

While the search results don't provide extensive information on RPL17 in disease contexts, we can discuss what is known about ribosomal proteins in pathological conditions more broadly:

• Cancer biology:

  • Ribosomal proteins, including RPL17, may be dysregulated in various cancers due to altered protein synthesis demands

  • RPL17 antibodies have been validated for use in pancreatic cancer tissue , suggesting potential research applications in oncology

  • Changes in expression or mutations in ribosomal proteins can contribute to cancer progression through effects on translation

• Ribosomopathies:

  • Mutations in ribosomal protein genes cause a class of disorders called ribosomopathies

  • While specific RPL17-associated ribosomopathies aren't mentioned in the search results, studying RPL17 may contribute to understanding these conditions

  • Ribosomal protein defects can affect tissue-specific translation, particularly in rapidly proliferating cells

• Neurodegenerative diseases:

  • Protein synthesis dysregulation is implicated in several neurodegenerative conditions

  • Studying RPL17 and other ribosomal components may provide insights into disease mechanisms

• Research applications in disease models:

  • RPL17 antibodies can be used to study changes in ribosome composition or function in disease models

  • IHC applications allow assessment of expression changes in patient-derived tissues

Researchers investigating RPL17 in disease contexts should consider combining antibody-based detection with functional studies to establish mechanistic links between this ribosomal protein and pathological processes.

What considerations are important when comparing data from different RPL17 antibodies?

When integrating results obtained using different RPL17 antibodies, researchers should consider several factors that influence data interpretation and comparability:

• Epitope differences:

  • Antibodies targeting different regions of RPL17 (N-terminal, C-terminal, internal regions) may yield different results based on epitope accessibility in various experimental conditions

  • C-terminal antibodies (AA 156-184) may detect different conformational states compared to antibodies against full-length protein (AA 1-184)

• Clone specificity:

  • Monoclonal antibodies (like clone 3G11) provide highly specific detection of single epitopes

  • Polyclonal antibodies offer broader epitope recognition but may show batch-to-batch variation

• Cross-reactivity profiles:

  • Species reactivity varies between antibodies: some detect only human RPL17, while others cross-react with mouse, rat, or monkey orthologs

  • Verify cross-reactivity claims experimentally when working with non-human samples

• Application-specific performance:

  • An antibody that performs well in Western blot may not be optimal for immunofluorescence

  • Review validation data for your specific application

• Quantitative comparisons:

  • Absolute quantification requires careful calibration between different antibodies

  • Consider using the same antibody across comparative studies where possible

• Documentation practices:

  • Always report complete antibody information in publications (catalog number, vendor, lot, dilution)

  • Include validation controls specific to each antibody used

A systematic approach to antibody selection and validation helps ensure reliable and reproducible research on RPL17 biology across different experimental platforms.

How can multiplexed detection of RPL17 with other ribosomal proteins be achieved?

Multiplexed detection allows simultaneous visualization or quantification of RPL17 alongside other ribosomal components:

• Multicolor immunofluorescence strategies:

  • Use RPL17 antibodies from different host species than antibodies against other target proteins

  • For co-detection with other rabbit-derived antibodies, consider using directly conjugated RPL17 antibodies (FITC-conjugated, etc.)

  • Employ fluorophores with distinct spectral properties to minimize bleed-through

  • Nuclear counterstaining (e.g., with Hoechst 33342) can provide contextual information

• Sequential immunostaining protocols:

  • For IHC applications with multiple rabbit antibodies, consider sequential staining with stripping steps between antibodies

  • Validate that epitope retrieval conditions are compatible for all target proteins

• Proximity ligation assays (PLA):

  • For studying RPL17 interactions with other ribosomal proteins with higher sensitivity than conventional co-immunofluorescence

  • Requires antibodies from different host species or directly conjugated antibodies

• Mass cytometry approaches:

  • Metal-tagged antibodies against RPL17 and other ribosomal components allow highly multiplexed detection

  • Particularly useful for single-cell analysis of ribosome composition

• Optimization considerations:

  • Antibody dilutions may need adjustment in multiplexed formats compared to single-staining protocols

  • Careful controls for cross-reactivity between primary and secondary antibodies are essential

These approaches expand the analytical power of RPL17 antibodies by placing this protein in its broader ribosomal context.

What are the critical parameters for successful immunoprecipitation of RPL17?

For efficient and specific immunoprecipitation of RPL17, consider these validated parameters:

• Antibody selection:

  • Choose antibodies specifically validated for IP applications

  • Recommended antibody amount: 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

• Cell/tissue preparation:

  • HeLa cells have been validated as a reliable source for RPL17 immunoprecipitation

  • Lysis buffers should preserve protein-protein interactions if studying RPL17 complexes

  • Gentle lysis conditions help maintain intact ribosomes if studying RPL17 in its native context

• Technical considerations:

  • Pre-clearing lysate with protein A/G beads reduces non-specific binding

  • Include appropriate negative controls (non-specific IgG, lysate from cells with RPL17 knockdown)

  • RNase treatment may help distinguish RNA-dependent from direct protein interactions

• Co-IP applications:

  • RPL17 can be used as bait to study interactions with other ribosomal proteins or translation factors

  • Cross-linking protocols can capture transient interactions in the translation machinery

• Analysis methods:

  • Western blot detection of immunoprecipitated RPL17 using a different antibody than used for IP

  • Mass spectrometry to identify co-precipitating proteins in an unbiased manner

Following these guidelines increases the likelihood of successfully isolating RPL17 and its associated complexes for downstream analysis.

What are the considerations for using RPL17 antibodies in ribosome profiling studies?

Integrating antibody-based methods with ribosome profiling requires careful consideration of several technical factors:

• Complementary approaches:

  • Ribosome profiling provides positional information about ribosomes on mRNAs

  • Antibody-based methods can verify the presence of RPL17 in these ribosomes

  • Combined approaches link compositional and functional aspects of translation

• Sample preparation compatibility:

  • Standard ribosome profiling protocols involve cycloheximide treatment and sucrose gradient fractionation

  • Verify that your RPL17 antibody recognizes the native conformation in fractionated samples

  • Consider potential epitope masking in assembled ribosomes

• Fractionation analysis:

  • Use Western blotting with RPL17 antibodies (1:1000-1:10000 dilution) to analyze different ribosomal fractions

  • Compare RPL17 distribution to other 60S ribosomal proteins and translation factors

  • Specialized gradient fraction collectors can facilitate systematic analysis

• Validation strategies:

  • Immunodepletion of RPL17-containing complexes prior to profiling

  • Correlation of RPL17 levels with specific translation events

  • Analysis of RPL17 association with specialized ribosomes (e.g., ER-bound vs. free ribosomes)

• Advanced applications:

  • Selective ribosome profiling using epitope-tagged RPL17

  • IP of RPL17-containing ribosomes followed by analysis of associated mRNAs

  • Spatial organization studies combining ribosome profiling with subcellular fractionation

These integrative approaches leverage the specificity of RPL17 antibodies to enhance mechanistic insights from ribosome profiling data.

How can RPL17 antibodies be used in single-cell analysis techniques?

Adapting RPL17 antibodies for single-cell applications opens new research possibilities:

• Single-cell immunofluorescence:

  • RPL17 antibodies have been validated for immunofluorescence at 1:200 dilution

  • Can reveal cell-to-cell variability in RPL17 expression or localization

  • Consider automated image analysis for quantitative assessment across many cells

• Flow cytometry applications:

  • Requires optimization of fixation and permeabilization for intracellular staining

  • FITC-conjugated RPL17 antibodies may be suitable for direct detection

  • May provide insights into heterogeneity of ribosome composition across cell populations

• Single-cell Western blot:

  • Emerging technology allowing protein quantification at single-cell resolution

  • RPL17 antibodies validated for traditional Western blot (1:1000-1:10000) may require optimization for these platforms

• Mass cytometry (CyTOF):

  • Metal-tagged antibodies enable highly multiplexed detection of many proteins

  • Could place RPL17 in broader context of cellular signaling networks

• Microfluidic approaches:

  • Droplet-based single-cell protein analysis

  • Requires highly specific antibodies with low background

• Considerations for data interpretation:

  • Account for cell cycle effects on ribosome biogenesis

  • Correlate with markers of cellular stress that may affect translation

These approaches extend RPL17 research beyond population averages to reveal heterogeneity in ribosome composition and function at the single-cell level.

What are the considerations for studying post-translational modifications of RPL17?

Investigating post-translational modifications (PTMs) of RPL17 requires specialized approaches:

• Antibody selection challenges:

  • Standard RPL17 antibodies detect total protein regardless of modification state

  • Modification-specific antibodies (phospho-specific, etc.) are required for direct PTM detection

  • Consider whether the antibody epitope (e.g., C-terminal region AA 156-184) contains potential modification sites

• Analytical strategies:

  • Combine immunoprecipitation using total RPL17 antibodies with mass spectrometry for PTM identification

  • 2D gel electrophoresis can resolve modified forms prior to Western blot detection

  • Phosphatase treatment prior to Western blot can confirm phosphorylation events

• Functional analysis approaches:

  • Compare ribosome activity with RPL17 modification status

  • Site-directed mutagenesis of predicted modification sites

  • Correlation of modifications with cellular stress responses or translation regulation

• Technical considerations:

  • Phosphatase inhibitors in lysis buffers preserve phosphorylation

  • Deacetylase inhibitors maintain acetylation modifications

  • Rapid sample processing minimizes artifactual modifications

While the search results don't specifically address RPL17 modifications, these approaches apply general principles of PTM research to this ribosomal protein, potentially revealing regulatory mechanisms controlling ribosome function through RPL17 modification.

How reliable are RPL17 antibodies for quantitative proteomics applications?

Using RPL17 antibodies in quantitative proteomics requires careful consideration of several factors:

• Antibody-based quantification methods:

  • Western blot: RPL17 antibodies provide semi-quantitative data at dilutions of 1:1000-1:10000

  • ELISA: Several RPL17 antibodies are validated for ELISA applications allowing more precise quantification

  • Reverse-phase protein arrays: Require highly specific antibodies with linear signal response

• Calibration approaches:

  • Use purified recombinant RPL17 protein to generate standard curves

  • Internal loading controls (housekeeping proteins) for relative quantification

  • Consideration of dynamic range limitations in different detection systems

• Validation requirements:

  • Verify linear response range for your specific antibody

  • Confirm specificity using knockdown/knockout controls

  • Assess consistency across different lots of the same antibody

• Alternative quantification methods:

  • Mass spectrometry-based absolute quantification (AQUA) provides antibody-independent measurement

  • Targeted proteomics (SRM/MRM) for RPL17-specific peptides

  • Comparison between antibody-based and MS-based quantification strengthens confidence in results

• Biological considerations:

  • RPL17 levels may change with cell cycle stage or growth conditions

  • Standardize sample collection and preparation to minimize variation

Careful method validation and appropriate controls allow reliable quantitative assessment of RPL17 levels across experimental conditions using antibody-based approaches.